- Home
- NX vs TSHA Comparison
NX vs TSHA Comparison
Compare NX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- TSHA
- Stock Information
- Founded
- NX 1927
- TSHA 2019
- Country
- NX United States
- TSHA United States
- Employees
- NX N/A
- TSHA N/A
- Industry
- NX Metal Fabrications
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- TSHA Health Care
- Exchange
- NX Nasdaq
- TSHA Nasdaq
- Market Cap
- NX 852.8M
- TSHA 728.4M
- IPO Year
- NX N/A
- TSHA 2020
- Fundamental
- Price
- NX $20.51
- TSHA $2.36
- Analyst Decision
- NX Strong Buy
- TSHA Strong Buy
- Analyst Count
- NX 1
- TSHA 5
- Target Price
- NX $38.00
- TSHA $8.20
- AVG Volume (30 Days)
- NX 580.4K
- TSHA 3.4M
- Earning Date
- NX 09-04-2025
- TSHA 08-11-2025
- Dividend Yield
- NX 1.56%
- TSHA N/A
- EPS Growth
- NX N/A
- TSHA N/A
- EPS
- NX 0.39
- TSHA N/A
- Revenue
- NX $1,625,028,000.00
- TSHA $7,224,000.00
- Revenue This Year
- NX $49.00
- TSHA N/A
- Revenue Next Year
- NX $2.99
- TSHA N/A
- P/E Ratio
- NX $52.20
- TSHA N/A
- Revenue Growth
- NX 47.66
- TSHA N/A
- 52 Week Low
- NX $15.30
- TSHA $1.05
- 52 Week High
- NX $34.97
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- NX 62.34
- TSHA 48.54
- Support Level
- NX $18.75
- TSHA $2.25
- Resistance Level
- NX $19.66
- TSHA $2.51
- Average True Range (ATR)
- NX 0.79
- TSHA 0.15
- MACD
- NX 0.17
- TSHA -0.03
- Stochastic Oscillator
- NX 75.84
- TSHA 48.78
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.